ESR1 and breast carcinoma: Therapies based on the use of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) have been developed, which are insensitive to resistance associated with mutations in the ER gene and result in prolonged progression-free survival in patients with advanced breast cancer [23].